Atara Biotherapeutics raises ~$16M in registered direct offering of common stock and pre-funded warrants

Atara Biotherapeutics, Inc.

Gross proceeds ~$16M from 834,237 shares at $6.61/share and pre-funded warrants for 1,587,108 shares at $6.6099.
Pre-funded warrants have exercise price $0.0001/share, exercisable immediately, no expiration.
Net proceeds to fund BLA approval activities for tab-cel and for working capital.
Underwriting agreement with TD Securities; offering expected to close May 16, 2025.
30-day lock-up on issuance and sale of company securities post-closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.